Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesOphthalmology/OptometryCigna Xipere Coverage Policy Update | OpenPayer
    Ask Trek AI about this page
    CurrentCignaPolicy IP0371

    Xipere

    Customize your policy alerts

    Sign up for Cigna Policy IP0371 alerts

    Get alerted when Policy IP0371 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and medical necessity coverage for Xipere for macular edema associated with non-infectious uveitis under Cigna-administered commercial health benefit plans.

    Policy Summary
    PayerCigna
    PolicyXipere
    Policy CodePolicy IP0371
    Change TypeMaterial update
    Effective DateNov 15, 2026
    Last ReviewSep 15, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization and document a trial of Triesence before requesting Xipere.
    SourceLink
    POLICY UPDATE CHANGES

    The policy added an adult age requirement for Xipere coverage.

    The policy added continuation-of-therapy criteria for patients currently receiving Xipere.

    The policy added specific dosing criteria for Xipere.

    Concomitant use of Xipere with another intravitreal corticosteroid was added as not medically necessary.

    The preferred product requirement was revised to require a trial of Triesence ophthalmic injectable suspension.

    4 mgRecommended Xipere dose per treated eye
    12 weeksMinimum permitted dosing interval
    6 months

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Initial therapy approval duration
    1 yearContinuation therapy approval duration
    ≥18 yearsMinimum patient age
    J3299Covered HCPCS code for Xipere

    Coverage Criteria

    Initial Therapy

    Covered for initial therapy when all required criteria are met, including the preferred product requirement.

    Initial therapy

    • Initial eligibility

      • Adult patient: Patient is at least 18 years of age.≥18 years
      • Qualifying disease: Patient has non-infectious uveitis, including pan, anterior, intermediate, or posterior uveitis.
      • Specialist prescriber: The medication is prescribed by, or in consultation with, an ophthalmologist.
      • Preferred product: The patient has tried Triesence ophthalmic injectable suspension.

        Applies to Employer Plans and Individual and Family Plans.

    Continuation Therapy

    Covered for continuation therapy when all required criteria are met.

    Continuation therapy

    • Continuation eligibility

      • Adult patient: Patient is at least 18 years of age.≥18 years
      • Qualifying disease: Patient has non-infectious uveitis, including pan, anterior, intermediate, or posterior uveitis.
      • Beneficial clinical response: According to the prescriber, the patient has demonstrated a beneficial clinical response.

        Examples include improvement or maintenance in best corrected visual acuity or visual field; reduction or maintenance in central subfield thickness; reduced rate of vision decline or risk of more severe vision loss; or reduced inflammation.

    Dosing Requirements

    The requested dosing must meet both dosing requirements.

    Dosing

    • Dose: The dose is 4 mg (0.1 mL of the 40 mg/mL injectable suspension) administered suprachoroidally for each eye being treated.4 mg per treated eye
    • Dosing interval: The dosing interval is not more frequent than once every 12 weeks.At least 12 weeks between doses

    Not Medically Necessary Use

    The following use is considered not medically necessary.

    Concomitant intravitreal corticosteroid use: Xipere used concomitantly with another intravitreally administered corticosteroid is not medically necessary.

    Examples include Ozurdex (dexamethasone intravitreal implant), Yutiq and Retisert (fluocinolone acetonide intravitreal implants), and Triesence (triamcinolone acetonide intravitreal injection).

    Concomitant use of Xipere with another intravitreal corticosteroid is not medically necessary. This includes use with Ozurdex (dexamethasone intravitreal implant), Yutiq (fluocinolone acetonide intravitreal implant), Retisert (fluocinolone acetonide intravitreal implant), or Triesence (triamcinolone acetonide intravitreal injection).

    Xipere is not medically necessary for indications other than the covered treatment of macular edema associated with non-infectious uveitis. Requests for other uses are not covered under this policy; the list of non-covered uses may be updated as new published data become available.

    Concomitant use of Xipere with any other intravitreal corticosteroid is considered not medically necessary. The policy states that there is no evidence to support administering Xipere together with another intravitreally administered corticosteroid.

    Coding and Authorization Parameters

    Medically Necessary HCPCS CodeHCPCSCovered
    J3299Injection, triamcinolone acetonide (Xipere), 1 mg
    Xipere Dose
    Dose per treated eye4 mg (0.1 mL of the 40 mg/mL injectable suspension)
    Dosing Interval
    Minimum dosing intervalNot more frequently than once every 12 weeks
    Initial Approval Duration
    Initial therapy approval6 months
    Continuation Approval Duration
    Continuation therapy approval

    Provider Submission and Denial Risks

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for benefit coverage of Xipere. Approval is recommended only when the applicable clinical criteria and dosing requirements are met, and the medication is prescribed by or in consultation with an ophthalmologist.

    • Initial therapy approval duration: 6 months.
    • Continuation approval duration: 1 year.
    • Requested dosing must meet the policy limits described below.
    Step Therapy

    Try Triesence First

    For Employer Plans and Individual and Family Plans, the preferred product requirement is met when the patient has tried Triesence ophthalmic injectable suspension before Xipere.

    • Applies to Xipere (triamcinolone acetonide 40 mg/mL suprachoroidal).
    • Document the Triesence trial for the applicable plan type.

    Clinical Background

    Xipere is a corticosteroid suspension containing triamcinolone acetonide that is administered by suprachoroidal injection, between the choroid and sclera. It is used for macular edema associated with uveitis. Uveitis is inflammation of the uveal tract and may be classified as anterior, intermediate, posterior, or panuveitis. Macular edema is a common complication of non-infectious uveitis and may cause photoreceptor damage and permanent vision loss.

    Key Definitions

    Uveitis
    DefinitionInflammation of the uveal tract, the vascular layer between the sclera and the neuroretina.
    Anatomical classificationsAnterior, intermediate, posterior, or panuveitis, based on the primary location of inflammation.
    Relevant policy classificationNon-infectious uveitis may be pan, anterior, intermediate, or posterior.
    Xipere
    FormulationCorticosteroid suspension containing triamcinolone acetonide 40 mg/mL.
    AdministrationSuprachoroidal injection between the choroid and sclera.
    Policy Summary
    PayerCigna
    PolicyXipere
    Policy CodePolicy IP0371
    Change TypeMaterial update
    Effective DateNov 15, 2026
    Last ReviewSep 15, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization and document a trial of Triesence before requesting Xipere.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Authorization ParametersProvider Submission and Denial RisksClinical BackgroundKey Definitions
  1. Specialist prescriber: The medication is prescribed by, or in consultation with, an ophthalmologist.
  2. 1 year
    Minimum Patient Age
    Minimum patient age≥ 18 years
    Documentation Required

    Document Clinical Eligibility

    For initial therapy, document that the patient is at least 18 years old, has macular edema associated with non-infectious uveitis, and is being treated by or in consultation with an ophthalmologist.

    • Eligible uveitis may be pan, anterior, intermediate, or posterior.
    • The covered indication is macular edema associated with uveitis.
    Documentation Required

    Document Beneficial Response

    For continuation requests, the prescriber must document that the patient has demonstrated a beneficial clinical response to Xipere.

    • Examples include improvement or maintenance in best corrected visual acuity or visual field.
    • Other examples include reduction or maintenance in central subfield thickness, reduced vision decline or risk of severe vision loss, or reduced inflammation.

    Unsupported block type: documentation

    Denial Risk

    Authorization or Coding Deficiencies Risk Denial

    Claims may be denied when required authorization is absent or when the claim is submitted without covered diagnosis or procedure codes under the applicable policy.

    • Obtain prior authorization before treatment when required.
    • Use the most appropriate codes in effect on the submission date.
    • Services billed for conditions or diagnoses not covered by the policy are not reimbursable.
    Denial Risk

    Initial Therapy Criteria Not Met

    An initial request may be denied when any required initial-therapy criterion is not met, including age, diagnosis, specialist involvement, or the preferred-product requirement.

    • Patient must be ≥ 18 years of age.
    • Patient must have non-infectious uveitis with associated macular edema; eligible types include pan, anterior, intermediate, or posterior uveitis.
    • Xipere must be prescribed by or in consultation with an ophthalmologist.
    • The patient must have tried Triesence ophthalmic injectable suspension.
    Denial Risk

    Continuation Criteria Not Met

    A continuation request may be denied when the patient does not meet the continuation criteria or when beneficial clinical response is not documented.

    • Patient must be ≥ 18 years of age.
    • Patient must have non-infectious uveitis with associated macular edema.
    • The prescriber must document a beneficial clinical response.
    • Xipere must be prescribed by or in consultation with an ophthalmologist.
    Denial Risk

    Dosing Outside Policy Limits

    Requested dosing outside the policy limits is not approved. The dose must be 4 mg per treated eye, administered suprachoroidally, with an interval no more frequent than once every 12 weeks.

    • Do not exceed 4 mg (0.1 mL of 40 mg/mL suspension) for each eye being treated.
    • Do not administer more frequently than once every 12 weeks.
    Denial Risk

    Concomitant Intravitreal Corticosteroid Use

    Concomitant use of Xipere with another intravitreal corticosteroid is considered not medically necessary because the policy identifies insufficient evidence to support the combination.

    • Examples include Ozurdex (dexamethasone intravitreal implant), Yutiq (fluocinolone acetonide intravitreal implant), Retisert (fluocinolone acetonide intravitreal implant), and Triesence (triamcinolone acetonide intravitreal injection).
    Denial Risk

    Non-Covered Indication

    Xipere for any use outside the covered indication of macular edema associated with non-infectious uveitis is considered not medically necessary and may be denied.

    • Covered indication: macular edema associated with non-infectious uveitis, including pan, anterior, intermediate, or posterior uveitis.
    • The list of non-covered uses may not be all inclusive and may be updated as new published data become available.
    Macular Edema Associated with Uveitis
    DefinitionSwelling involving the macula associated with uveitis.
    Covered indicationFDA-approved treatment of macular edema associated with uveitis, including macular edema associated with non-infectious uveitis.
    Clinical significanceIf left untreated, it may result in photoreceptor damage and permanent vision loss.